SEARCH THE AGT WEBSITE

Try these: HIVPKULiver CancerImmuno-oncologyGene TherapyBiotech Investment

Subscribe to Our Newsletter

Subscribe to our newsletter to keep up to date with all the latest news about American Gene Technologies!

Follow AGT on Social Media

AGT on Facebook

R&D at the biggest biopharmaceuticals has increased quite a bit in 2023! Oncology, neuroscience and cardiovascular are some of the biggest areas where @astrazeneca, @Johnson&johnson, @novartis, @roche and @merck are spending.loom.ly/9C1kW2U ... See MoreSee Less
View on Facebook
On Monday, the FDA approved @orchard_tx Lenmeldy for early juvenile metachromatic leukodystrophy! No treatment previously existed for this rare childhood genetic disease that leads to loss of motor & cognitive skill & eventually death.loom.ly/1PQPsBcloom.ly/1ONp2L4 ... See MoreSee Less
View on Facebook
Despite weak investment in 2023, new drug approvals reached a high with approvals in five gene therapies, weight loss & Alzheimer's. loom.ly/k0On_r0 ... See MoreSee Less
View on Facebook
#ICYMI, our Chief Science Officer, Jeff Boyle, PhD, was featured in the 2024 March issue of Pharm Tech, providing commentary and insight on the development of Gamma-Delta T-cell therapies – and how we are leveraging #genetherapy. Read more: brnw.ch/21wI3Nx ... See MoreSee Less
View on Facebook